RxDoctor Payments DataLook up a doctor →

Michael Bestawros

Clinical Cardiac Electrophysiology · Albuquerque, NMNPI 1699909879

Payments from drug & device makers

$314,421in general payments, 2019–2025

Across 563 payments — averaging $558.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$118K
  • Atricure, Inc.$100K
  • Medical Device Business Services, Inc.$74K
  • Boston Scientific$11K
  • Biosense Webster, Inc.$6K
  • Medtronic$4K
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$62,60076%
  • Speaking & faculty fees$6,0007%
  • Travel & lodging$4,0835%
  • Food & beverage$9,52712%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$379,962
Medicare patients
3,287
Services billed
6,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban517$579,454
XareltoRivaroxaban43$45,685
EntrestoSacubitril/Valsartan19$21,532
Dofetilide13$11,419
Flecainide Acetate156$5,677
Metoprolol Succinate188$2,668
Carvedilol168$2,071
Amiodarone Hcl13$1,163
ClopidogrelClopidogrel Bisulfate68$954
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$853
Atorvastatin Calcium52$718
Losartan Potassium51$603
Rosuvastatin Calcium26$546
Lisinopril55$434
Metoprolol Tartrate63$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$579,454517 claims
Johnson & JohnsonXarelto$78$45,68543 claims
NovartisEntresto$135$21,53219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →